Design Considerations for Devices Intended for Home Use; Guidance for Industry and Food and Drug Administration Staff; Availability, 45447-45448 [2014-18470]
Download as PDF
Federal Register / Vol. 79, No. 150 / Tuesday, August 5, 2014 / Notices
and reported by SLHs participating in
ACL-funded Model Approaches projects
will be comparable from one SLH to
another and apply standard/uniform
terminology consistently across Model
Approaches projects. The consistent and
uniform data will be used to illustrate
the effectiveness of Model Approaches
states in reaching key target populations
under the OAA with much needed
‘‘priority’’ legal assistance through
SLHs. The data collected will also
inform and drive ongoing ACL policy
related to increasing the number of
states that have a SLH as a sustained,
and permanent feature of integrated and
cost effective legal service delivery
systems targeted to those most in need.
Anticipated data collection and
reporting requirements would apply to
SLHs operating as lead partners in 2014
Model Approaches Phase I and Phase II,
with a total of 11 SLHs operational
during the 3 year project period.
ACL estimates the burden of this
collection of information as follows: 11
SLHs would be asked to respond
annually pursuant to data collection
tools that should require an average
burden of 2.5 hours per SLH per year or
a total 27.5 hours for all complying
SLHs operating under Model
Approaches projects. The proposed data
collection tools may be found on the
CERA Web site for review at: https://
www.legalhotlines.org/uploads/1/6/9/1/
16912868/reportingguidelinesforsenior
legalhelplines.pdf.
Dated: July 31, 2014.
Kathy Greenlee,
Administrator and Assistant Secretary for
Aging.
[FR Doc. 2014–18463 Filed 8–4–14; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–D–1161]
Design Considerations for Devices
Intended for Home Use; Guidance for
Industry and Food and Drug
Administration Staff; Availability
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on DSK4VPTVN1PROD with NOTICES
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of the guidance entitled
‘‘Design Considerations for Devices
Intended for Home Use.’’ This
document is intended to assist
manufacturers in designing and
developing home use medical devices
SUMMARY:
VerDate Mar<15>2010
18:16 Aug 04, 2014
Jkt 232001
that comply with applicable standards
of safety and effectiveness and other
regulatory requirements. Devices used
in the home or other non-clinical
environments are associated with
unique risks created by the interactions
among the user (often a layperson), the
use environment, and the device. This
document identifies several factors that
manufacturers should consider,
especially during device design and
development, and provides
recommendations for minimizing these
unique risks.
DATES: Submit either electronic or
written comments on this guidance at
any time. General comments on Agency
guidance documents are welcome at any
time.
ADDRESSES: An electronic copy of the
guidance document is available for
download from the Internet. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the guidance
document entitled ‘‘Design
Considerations for Devices Intended for
Home Use’’ to the Office of the Center
Director, Guidance and Policy
Development, Center for Devices and
Radiological Health (CDRH), Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 5431,
Silver Spring, MD 20993–0002.
Alternatively, you may submit written
requests for single copies of the
guidance to the Office of
Communication, Outreach, and
Development, Center for Biologics
Evaluation and Research (CBER), Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 3128,
Silver Spring, MD 20993–0002. Send
one self-addressed adhesive label to the
office that you are ordering from to
assist that office in processing your
request.
Submit electronic comments on the
guidance to https://www.regulations.gov.
Submit written comments to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852. Identify comments with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: For
information concerning the guidance as
it relates to devices regulated by CDRH:
Mary Brady, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5426, Silver Spring,
MD 20993–0002, 301–796–6089.
For information concerning the
guidance as it relates to devices
regulated by CBER: Stephen Ripley,
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
45447
Center for Biologics Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 7301, Silver Spring,
MD 20993–0002, 240–402–7911.
SUPPLEMENTARY INFORMATION:
I. Background
For a variety of reasons, use of devices
outside professional healthcare facilities
is on the rise. First, the U.S. population
is aging, and the elderly are more likely
to live with chronic diseases that
require daily medical care at home.
Second, due to medical advancements,
many individuals with chronic diseases
are living longer but are dependent on
home medical care. Finally, an
increasing focus on reducing healthcare
costs for patients of all ages has spurred
the growth of the home health care
market. Integral to the home health care
market are home use devices. Although
home use devices provide significant
benefits to patients and families,
including quality of life improvements
and cost savings, they are also
associated with unique risks.
Minimizing the risks posed by home use
devices can greatly improve the public
health.
This guidance provides
recommendations for designing and
developing medical devices intended
for home use through considerations
involving the physical environment, the
user, the device or system, the labeling,
and human factors. This should result
in a safe and easier-to-use device,
minimize use error, and reduce the
likelihood that adverse events will
occur. The recommendations in the
guidance apply to both prescription and
over-the-counter medical devices that
are intended for use in the home or
other non-clinical environments.
In the Federal Register of December
13, 2012 (77 FR 74195), FDA announced
the availability of the draft guidance
document. Interested persons were
invited to comment by March 13, 2013.
FDA reviewed the comments and
revised the guidance as appropriate.
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the Agency’s
current thinking on design
considerations for devices intended for
home use. It does not create or confer
any rights for or on any person and does
not operate to bind FDA or the public.
An alternative approach may be used if
such approach satisfies the
requirements of the applicable statute
and regulations.
E:\FR\FM\05AUN1.SGM
05AUN1
45448
Federal Register / Vol. 79, No. 150 / Tuesday, August 5, 2014 / Notices
III. Electronic Access
Persons interested in obtaining a copy
of the guidance may do so by
downloading an electronic copy from
the Internet. A search capability for all
CDRH guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm.
Guidance documents are also available
at https://www.regulations.gov or from
CBER at https://www.fda.gov/Biologics
BloodVaccines/GuidanceCompliance
RegulatoryInformation/default.htm.
Persons unable to download an
electronic copy of ‘‘Design
Considerations for Devices Intended for
Home Use’’ may send an email request
to CDRH-Guidance@fda.hhs.gov to
receive an electronic copy of the
document. Please use the document
number 1750 to identify the guidance
you are requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to currently
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
21 CFR part 801 and 21 CFR 809.10
have been approved under OMB control
number 0910–0485; the collections of
information in 21 CFR part 803 have
been approved under OMB control
number 0910–0437; the collections of
information in 21 CFR part 807, subpart
E have been approved under OMB
control number 0910–0120; the
collections of information in 21 CFR
part 814 have been approved under
OMB control number 0910–0231; the
collections of information in 21 CFR
part 820 have been approved under
OMB control number 0910–0073; and
the collections of information in Form
FDA 3500A have been approved under
OMB control number 0910–0291.
mstockstill on DSK4VPTVN1PROD with NOTICES
V. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
VerDate Mar<15>2010
18:16 Aug 04, 2014
Jkt 232001
Dated: July 31, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–18470 Filed 8–4–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–D–1165]
Draft Guidance for Industry on
Reference Product Exclusivity for
Biological Products Filed Under
Section 351(a) of the Public Health
Service Act; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance for
industry entitled ‘‘Reference Product
Exclusivity for Biological Products Filed
Under Section 351(a) of the PHS Act.’’
This draft guidance is intended to assist
sponsors developing biological
products, sponsors holding biologics
license applications (BLAs), and other
interested parties in providing
information and data that will help the
Agency determine the date of first
licensure for a reference product under
351(k)(7)(C) of the Public Health Service
Act (PHS Act), as added by the Biologics
Price Competition and Innovation Act of
2009 (BPCI Act). The BPCI Act amends
the PHS Act and other statutes to create
an abbreviated licensure pathway for
biological products shown to be
biosimilar to, or interchangeable with,
an FDA-licensed biological reference
product.
SUMMARY:
Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by October 6,
2014. Submit either electronic or
written comments concerning the
proposed collection of information by
October 6, 2014.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 2201,
Silver Spring, MD 20993–0002, or Office
of Communication, Outreach and
Development (HFM–40), Center for
DATES:
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
Biologics Evaluation and Research,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm.
3128, Silver Spring, MD 20993–0002.
Send one self-addressed adhesive label
to assist that office in processing your
requests. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance document.
Submit electronic comments on the
draft guidance to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Sandra Benton, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6340,
Silver Spring, MD 20993–0002, 301–
796–1042; or Stephen Ripley, Center for
Biologics Evaluation and Research
(HFM–17), Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 7301, Silver Spring,
MD 20993–0002, 240–402–7911.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a draft guidance for industry entitled
‘‘Reference Product Exclusivity for
Biological Products Filed Under Section
351(a) of the PHS Act.’’ This draft
guidance is intended to assist sponsors
who are developing biological products,
sponsors of BLAs, and other interested
parties in providing information that
will help the Agency determine the date
of first licensure for a reference product
under 351(k)(7)(C) of the Public Health
Service Act (PHS Act) as added by the
Biologics Price Competition and
Innovation Act of 2009 (BPCI Act).
The BPCI Act amends the PHS Act
and other statutes to create an
abbreviated licensure pathway for
biological products shown to be
biosimilar to, or interchangeable with,
an FDA-licensed biological reference
product (see sections 7001 through 7003
of the Patient Protection and Affordable
Care Act (Pub. L. 111–148)). Section
351(k)(7) of the PHS Act, entitled
‘‘Exclusivity for Reference Product,’’
describes reference product exclusivity,
the period of time in which a 351(k)
sponsor is not permitted to submit and
FDA is not permitted to license a 351(k)
application that references a reference
product, the single biological product
licensed under section 351(a) of the PHS
Act against which a biological product
is evaluated in a 351(k) application.
Under this section, exclusivity for the
reference product is described in terms
E:\FR\FM\05AUN1.SGM
05AUN1
Agencies
[Federal Register Volume 79, Number 150 (Tuesday, August 5, 2014)]
[Notices]
[Pages 45447-45448]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-18470]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-D-1161]
Design Considerations for Devices Intended for Home Use; Guidance
for Industry and Food and Drug Administration Staff; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of the guidance entitled ``Design Considerations for
Devices Intended for Home Use.'' This document is intended to assist
manufacturers in designing and developing home use medical devices that
comply with applicable standards of safety and effectiveness and other
regulatory requirements. Devices used in the home or other non-clinical
environments are associated with unique risks created by the
interactions among the user (often a layperson), the use environment,
and the device. This document identifies several factors that
manufacturers should consider, especially during device design and
development, and provides recommendations for minimizing these unique
risks.
DATES: Submit either electronic or written comments on this guidance at
any time. General comments on Agency guidance documents are welcome at
any time.
ADDRESSES: An electronic copy of the guidance document is available for
download from the Internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the guidance document entitled
``Design Considerations for Devices Intended for Home Use'' to the
Office of the Center Director, Guidance and Policy Development, Center
for Devices and Radiological Health (CDRH), Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver
Spring, MD 20993-0002. Alternatively, you may submit written requests
for single copies of the guidance to the Office of Communication,
Outreach, and Development, Center for Biologics Evaluation and Research
(CBER), Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
71, Rm. 3128, Silver Spring, MD 20993-0002. Send one self-addressed
adhesive label to the office that you are ordering from to assist that
office in processing your request.
Submit electronic comments on the guidance to https://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852. Identify comments with the docket number
found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: For information concerning the
guidance as it relates to devices regulated by CDRH: Mary Brady, Center
for Devices and Radiological Health, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 66, Rm. 5426, Silver Spring, MD 20993-
0002, 301-796-6089.
For information concerning the guidance as it relates to devices
regulated by CBER: Stephen Ripley, Center for Biologics Evaluation and
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911.
SUPPLEMENTARY INFORMATION:
I. Background
For a variety of reasons, use of devices outside professional
healthcare facilities is on the rise. First, the U.S. population is
aging, and the elderly are more likely to live with chronic diseases
that require daily medical care at home. Second, due to medical
advancements, many individuals with chronic diseases are living longer
but are dependent on home medical care. Finally, an increasing focus on
reducing healthcare costs for patients of all ages has spurred the
growth of the home health care market. Integral to the home health care
market are home use devices. Although home use devices provide
significant benefits to patients and families, including quality of
life improvements and cost savings, they are also associated with
unique risks. Minimizing the risks posed by home use devices can
greatly improve the public health.
This guidance provides recommendations for designing and developing
medical devices intended for home use through considerations involving
the physical environment, the user, the device or system, the labeling,
and human factors. This should result in a safe and easier-to-use
device, minimize use error, and reduce the likelihood that adverse
events will occur. The recommendations in the guidance apply to both
prescription and over-the-counter medical devices that are intended for
use in the home or other non-clinical environments.
In the Federal Register of December 13, 2012 (77 FR 74195), FDA
announced the availability of the draft guidance document. Interested
persons were invited to comment by March 13, 2013. FDA reviewed the
comments and revised the guidance as appropriate.
II. Significance of Guidance
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
Agency's current thinking on design considerations for devices intended
for home use. It does not create or confer any rights for or on any
person and does not operate to bind FDA or the public. An alternative
approach may be used if such approach satisfies the requirements of the
applicable statute and regulations.
[[Page 45448]]
III. Electronic Access
Persons interested in obtaining a copy of the guidance may do so by
downloading an electronic copy from the Internet. A search capability
for all CDRH guidance documents is available at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance documents are also available at https://www.regulations.gov or from CBER at https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm. Persons unable to download an electronic copy of ``Design
Considerations for Devices Intended for Home Use'' may send an email
request to CDRH-Guidance@fda.hhs.gov to receive an electronic copy of
the document. Please use the document number 1750 to identify the
guidance you are requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to currently approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in 21 CFR part 801 and 21 CFR 809.10 have
been approved under OMB control number 0910-0485; the collections of
information in 21 CFR part 803 have been approved under OMB control
number 0910-0437; the collections of information in 21 CFR part 807,
subpart E have been approved under OMB control number 0910-0120; the
collections of information in 21 CFR part 814 have been approved under
OMB control number 0910-0231; the collections of information in 21 CFR
part 820 have been approved under OMB control number 0910-0073; and the
collections of information in Form FDA 3500A have been approved under
OMB control number 0910-0291.
V. Comments
Interested persons may submit either electronic comments regarding
this document to https://www.regulations.gov or written comments to the
Division of Dockets Management (see ADDRESSES). It is only necessary to
send one set of comments. Identify comments with the docket number
found in brackets in the heading of this document. Received comments
may be seen in the Division of Dockets Management between 9 a.m. and 4
p.m., Monday through Friday, and will be posted to the docket at https://www.regulations.gov.
Dated: July 31, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-18470 Filed 8-4-14; 8:45 am]
BILLING CODE 4164-01-P